Mechanistic Perspectives of Maslinic Acid in Targeting Inflammation

Biochemistry Research International

Volumn 2015, Issue , 2015, Pages

  Yap, Wei Hsum ^a   Lim, Yang Mooi ^b  

^a TAYLOR S UNIVERSITY   (Malaysia)

^b UNIVERSITI TUNKU ABDUL RAHMAN   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944205543     PISSN: 20902247     EISSN: 20902255     Source Type: Journal    
DOI: 10.1155/2015/279356     Document Type: Review

References (82)

1. H.-X. Xu, F.-Q. Zeng, M. Wan, and K.-Y. Sim, "Anti-HIV triterpene acids from Geum japonicum," Journal of Natural Products, vol. 59, no. 7, pp. 643-645, 1996.
2. D.-H. Kim, K.-M. Han, I.-S. Chung et al. , "Triterpenoids from the flower of Campsis grandiflora K. Schum. as human acyl-CoA: cholesterol acyltransferase inhibitors," Archives of Pharmacal Research, vol. 28, no. 5, pp. 550-556, 2005.
3. N. Kalogeropoulos, A. Chiou, M. Ioannou, V. T. Karathanos,M. Hassapidou, and N. K. Andrikopoulos, "Nutritional evaluation and bioactive microconstituents (phytosterols, tocopherols, polyphenols, triterpenic acids) in cooked dry legumes usually consumed in the Mediterranean countries," Food Chemistry, vol. 121, no. 3, pp. 682-690, 2010.
4. M.-C. Yin, M.-C. Lin, M.-C. Mong, and C.-Y. Lin, "Bioavailability, distribution, and antioxidative effects of selected triterpenes in mice," Journal of Agricultural and Food Chemistry, vol. 60,no. 31, pp. 7697-7701, 2012.
5. C. Romero, A. Garca, E. Medina, M. V. Ruz-Méndez, A. D. Castro, and M. Brenes, "Triterpenic acids in table olives," Food Chemistry, vol. 118, no. 3, pp. 670-674, 2010.
6. M. C. Pérez-Camino and A. Cert, "Quantitative determination of hydroxy pentacyclic triterpene acids in vegetable oils," Journal of Agricultural and Food Chemistry, vol. 47, no. 4, pp. 1558-1562, 1999.
7. G. Bianchi, N. Pozzi, and G. Vlahov, "Pentacyclic triterpene acids in olives," Phytochemistry, vol. 37, no. 1, pp. 205-207, 1994.
8. M. Yang, J. W. Guang, J. W. Su et al. , "Quantitative analysis of 23-hydroxybetulinic acid in mouse plasma using electrospray liquid chromatography/mass spectrometry," Rapid Communications inMass Spectrometry, vol. 19, no. 12, pp. 1619-1623, 2005.
9. M. E. Juan, U. Wenzel, V. Ruiz-Gutierrez, H. Daniel, and J. M. Planas, "Olive fruit extracts inhibit proliferation and induce apoptosis in HT-29 human colon cancer cells," The Journal of Nutrition, vol. 136, no. 10, pp. 2553-2557, 2006.
10. H. Lu, C. Xi, J. Chen, andW. Li, "Determination of triterpenoid acids in leaves of Eriobotrya japonica collected at in different seasons," Zhongguo Zhong Yao Za Zhi, vol. 34, no. 18, pp. 2353-2355, 2009.
11. N. Banno, T. Akihisa, H. Tokuda et al. , "Anti-inflammatory and antitumor-promoting effects of the triterpene acids from the leaves of Eriobotrya japonica," Biological and Pharmaceutical Bulletin, vol. 28, no. 10, pp. 1995-1999, 2005.
12. D.-H. Kim, K.-M. Han, I.-S. Chung et al. , "Triterpenoids from the flower of Campsis grandiflora K. Schum. as human Acyl-CoA: cholesterol acyltransferase inhibitors," Archives of Pharmacal Research, vol. 28, no. 5, pp. 550-556, 2005.
13. Z. M. Zou and P. Z. Cong, "Studies on the chemical constituents from roots of Agastache rugosa," Yao Xue Xue Bao, vol. 26, pp. 906-910, 1991.
14. C. Li, Z. Yang, C. Zhai et al. , "Maslinic acid potentiates the antitumor activity of tumor necrosis factor by inhibiting NF-B signaling pathway," Molecular Cancer, vol. 9, article 73, 2010.
15. S. Sánchez-Tena, F. J. Reyes-Zurita, S. Daz-Moralli et al. , "Maslinic acid-enriched diet decreases intestinal tumorigenesis in ApcMin/+ mice through transcriptomic and metabolomic reprogramming," PLoS ONE, vol. 8, no. 3, Article ID e59392, 2013.
16. A. Márquez Martn, R. de la Puerta Vázquez, A. Fernández-Arche, and V. Ruiz-Gutiérrez, "Supressive effect of maslinic acid from pomace olive oil on oxidative stress and cytokine production in stimulated murine macrophages," Free Radical Research, vol. 40, no. 3, pp. 295-302, 2006.
17. L. Huang, T. Guan, Y. Qian et al. , "Anti-inflammatory effects of maslinic acid, a natural triterpene, in cultured cortical astrocytes via suppression of nuclear factor-kappa B," European Journal of Pharmacology, vol. 672, no. 1-3, pp. 169-174, 2011.
18. A. Hussain Shaik, S. N. Rasool,M. A. Kareem, G. S. Krushna, P. M. Akhtar, and K. L. Devi, "Maslinic acid protects against isoproterenol-induced cardiotoxicity in albino Wistar rats," Journal of Medicinal Food, vol. 15, no. 8, pp. 741-746, 2012.
19. A. Parra, F. Rivas, P. E. Lopez et al. , "Solution-and solid-phase synthesis and anti-HIV activity of maslinic acid derivatives containing amino acids and peptides," Bioorganic & Medicinal Chemistry, vol. 17, no. 3, pp. 1139-1145, 2009.
20. C. Moneriz, J. Mestres, J. M. Bautista, A. Diez, and A. Puyet, "Multi-targeted activity of maslinic acid as an antimalarial natural compound," FEBS Journal, vol. 278, no. 16, pp. 2951-2961, 2011.
21. Y. Qian, T. Guan, X. Tang et al. , "Maslinic acid, a natural triterpenoid compound from Olea europaea, protects cortical neurons against oxygen-glucose deprivation-induced injury," European Journal of Pharmacology, vol. 670, no. 1, pp. 148-153, 2011.
22. M. P. Montilla, A. Agil, M. C. Navarro et al. , "Antioxidant activity of maslinic acid, a triterpene derivative obtained from Olea europaea," PlantaMedica, vol. 69, no. 5, pp. 472-474, 2003.
23. M. Sánchez-González, G. Lozano-Mena, M. E. Juan,A. Garca-Granados, and J. M. Planas, "Assessment of the safety ofmaslinic acid, a bioactive compound from Olea europaea L. ," Molecular Nutrition and Food Research, vol. 57, no. 2, pp. 339-346, 2013.
24. M. Sun, Y. Tang, T. Ding, M. Liu, and X. Wang, "Investigation of cytochrome P450 inhibitory properties of maslinic acid, a bioactive compound from Olea europaea L. , and its structureactivity relationship," Phytomedicine, vol. 22, no. 1, pp. 56-65, 2015.
25. J. D. Connolly and R. A. Hill, "Triterpenoids," Natural Product Reports, vol. 19, no. 4, pp. 494-513, 2002.
26. R. Xu, G. C. Fazio, and S. P. T. Matsuda, "On the origins of triterpenoid skeletal diversity," Phytochemistry, vol. 65,no. 3, pp. 261-291, 2004.
27. J. Glinski and K. L. Branly, "Pentacyclic triterpenes," US Patent 6303589, 2002.
28. M. B. Sporn, K. T. Liby, M. M. Yore, L. Fu, J. M. Lopchuk, and G. W. Gribble, "New synthetic triterpenoids: Potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress," Journal of Natural Products, vol. 74, no. 3, pp. 537-545, 2011.
29. M. Del Carmen Recio, R. M. Giner, S. Máñez, and J. L. Ros, "Structural requirements for the anti-inflammatory activity of natural triterpenoids," PlantaMedica, vol. 61, no. 2, pp. 182-185, 1995.
30. H. L. Ziegler, H. Franzyk, M. Sairafianpour et al. , "Erythrocyte membrane modifying agents and the inhibition of Plasmodium falciparum growth: structure-activity relationships for betulinic acid analogues," Bioorganic andMedicinal Chemistry, vol. 12,no. 1, pp. 119-127, 2004.
31. J. Prades, O. Vögler, R. Alemany et al. , "Plant pentacyclic triterpenic acids as modulators of lipid membrane physical properties," Biochimica et Biophysica Acta-Biomembranes, vol. 1808, no. 3, pp. 752-760, 2011.
32. T. Syrovets, B. Büchele, E. Gedig, J. R. Slupsky, and T. Simmet, "Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and II,"Molecular Pharmacology, vol. 58, no. 1, pp. 71-81, 2000.
33. A. Marquez-Martin, R. De La Puerta, A. Fernandez-Arche, V. Ruiz-Gutierrez, and P. Yaqoob, "Modulation of cytokine secretion by pentacyclic triterpenes from olive pomace oil in human mononuclear cells," Cytokine, vol. 36, no. 5-6, pp. 211-217, 2006.
34. E. Ricciotti and G. A. Fitzgerald, "Prostaglandins and inflammation," Arteriosclerosis,Thrombosis, and Vascular Biology, vol. 31, no. 5, pp. 986-1000, 2011.
35. M. J. Stables and D. W. Gilroy, "Old and new generation lipid mediators in acute inflammation and resolution," Progress in Lipid Research, vol. 50, no. 1, pp. 35-51, 2011.
36. P. Piper and J. Vane, "The release of prostaglandins from lung and other tissues," Annals of the New York Academy of Sciences, vol. 180, pp. 363-385, 1971.
37. C. N. Serhan, M. Hamberg, and B. Samuelsson, "Trihydroxytetraenes: A novel series of compounds formed from arachidonic acid in human leukocytes," Biochemical and Biophysical Research Communications, vol. 118, no. 3, pp. 943-949, 1984.
38. B. Samuelsson, S.-E. Dahlen, J. A. Lindgren,C. A. Rouzer, andC. N. Serhan, "Leukotrienes and lipoxins: structures, biosynthesis, and biological effects," Science, vol. 237, no. 4819, pp. 1171-1176, 1987.
39. J. H. Capdevilla, J. R. Falck, E. Dishman, and A. Karara, "Cytochrome P-450 arachidonate oxygenase,"Methods in Enzymology, vol. 187, pp. 385-394, 1990.
40. E. M. Smyth, T. Grosser, M. Wang, Y. Yu, and G. A. FitzGerald, "Prostanoids in health and disease," Journal of Lipid Research, vol. 50, pp. S423-S428, 2009.
41. M. Hamberg and B. Samuelsson, "Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis," Proceedings of the National Academy of Sciences of the United States of America, vol. 70, no. 3, pp. 899-903, 1973.
42. D. H. Nugteren and E. Hazelhof, "Isolation and properties of intermediates in prostaglandin biosynthesis," Biochimica et Biophysica Acta, vol. 326, no. 3, pp. 448-461, 1973.
43. R. N. Dubois, S. B. Abramson, L. Crofford et al. , "Cyclooxygenase in biology and disease," The FASEB Journal, vol. 12, no. 12, pp. 1063-1073, 1998.
44. J. D. Morrow, W. G. Parsons III, and L. J. Roberts II, "Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid," Prostaglandins, vol. 38, no. 2, pp. 263-274, 1989.
45. Y. Tanaka, S. L. Ward, and W. L. Smith, "Immunochemical and kinetic evidence for two different prostaglandin Hprostaglandin E isomerases in sheep vesicular gland microsomes," Journal of Biological Chemistry, vol. 262, no. 3, pp. 1374-1381, 1987.
46. H. Hayashi, Y. Fujii, K. Watanabe, Y. Urade, and O. Hayaishi, "Enzymatic conversion of prostaglandin H2 to prostaglandin F(2) by aldehyde reductase from human liver: comparison to the prostaglandin F synthetase from bovine lung," Journal of Biological Chemistry, vol. 264, no. 2, pp. 1036-1040, 1989.
47. S. Moncada, R. Gryglewski, S. Bunting, and J. R. Vane, "An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation," Nature, vol. 263, no. 5579, pp. 663-665, 1976.
48. V. Ullrich and M. Haurand, "Thromboxane synthase as a cytochrome P450 enzyme," Advances in Prostaglandin, Thromboxane, and Leukotriene Research, vol. 11, pp. 105-110, 1983.
49. C. E. Trebino, J. L. Stock, C. P. Gibbons et al. , "Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 9044-9049, 2003.
50. D. F. Legler, M. Bruckner, E. Uetz-von Allmen, and P. Krause, "Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances," International Journal of Biochemistry & Cell Biology, vol. 42, no. 2, pp. 198-201, 2010.
51. A. J. Lewis, D. J. Nelson, and M. F. Sugrue, "On the ability of prostaglandin E1 and arachidonic acid to modulate experimentally induced oedema in the rat paw," British Journal of Pharmacology, vol. 55, no. 1, pp. 51-56, 1975.
52. G. Kaley, T. H. Hintze,M. Panzenbeck, and E. J. Messina, "Role of prostaglandins in microcirculatory function," Advances in Prostaglandin,Thromboxane, and Leukotriene Research, vol. 13, pp. 27-35, 1985.
53. A. N. Hata and R. M. Breyer, "Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation," Pharmacology & Therapeutics, vol. 103, no. 2, pp. 147-166, 2004.
54. T. Moriyama, T. Higashi, K. Togashi et al. , "Sensitization of TRPVI by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins," Molecular Pain, vol. 1, article 3, 2005.
55. T. Minami, H. Nakano, T. Kobayashi et al. , "Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice," British Journal of Pharmacology, vol. 133, no. 3, pp. 438-444, 2001.
56. M. C. Catley, J. E. Chivers, L. M. Cambridge et al. , "IL-1 beta-dependent activation of NF-kappa B mediates PGE2 release via the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase," FEBS Letters, vol. 547, no. 1-3, pp. 75-79, 2003.
57. K. Yamamoto, T. Arakawa, N. Ueda, and S. Yamamoto, "Transcriptional roles of nuclear factor B and nuclear factorinterleukin-6 in the tumor necrosis factor-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells," Journal of Biological Chemistry, vol. 270, no. 52, pp. 31315-31320, 1995.
58. F. D'Acquisto, T. Iuvone, L. Rombolà, L. Sautebin, M. Di Rosa, and R. Carnuccio, "Involvement ofNF-kappaB in the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages," FEBS Letters, vol. 418, no. 1-2, pp. 175-178, 1997.
59. T. Ochi, Y. Ohkubo, and S. Mutoh, "Role of cyclooxygenase-2, but not cyclooxygenase-1, on type II collagen-induced arthritis in DBA/1J mice," Biochemical Pharmacology, vol. 66, no. 6, pp. 1055-1060, 2003.
60. L. K. Myers, A. H. Kang, A. E. Postlethwaite et al. , "The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis," Arthritis & Rheumatism, vol. 43, no. 12, pp. 2687-2693, 2000.
61. M. Chen, E. Boilard, P. A. Nigrovic et al. , "Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serum-transfer arthritis," Arthritis & Rheumatism, vol. 58, no. 5, pp. 1354-1365, 2008.
62. I. A. Mardini and G. A. FitzGerald, "Selective inhibitors of cyclooxygenase-2: A growing class of anti-inflammatory drugs," Molecular Interventions, vol. 1, no. 1, pp. 30-38, 2001.
63. C. D. Funk and G. A. FitzGerald, "COX-2 inhibitors and cardiovascular risk," Journal of Cardiovascular Pharmacology, vol. 50, no. 5, pp. 470-479, 2007.
64. R. Zamora, Y. Vodovotz, and T. R. Billiar, "Inducible nitric oxide synthase and inflammatory diseases," Molecular Medicine, vol. 6, no. 5, pp. 347-373, 2000.
65. P. Osuna, "Use of maslinic acid for the treatment of diseases and the symptoms thereof by means of cox-2 inhibition," US Patent US 20110105611A1, 2011.
66. E. Fosslien, "Molecular pathology of cyclooxygenase-2 in neoplasia," Annals of Clinical and Laboratory Science, vol. 30, no. 1, pp. 3-21, 2000.
67. S. Y. Park, C. W. Nho, D. Y. Kwon, Y.-H. Kang, K. W. Lee, and J. H. Y. Park, "Maslinic acid inhibits the metastatic capacity of DU145 human prostate cancer cells: Possible mediation via hypoxia-inducible factor-1signalling," British Journal of Nutrition, vol. 109, no. 2, pp. 210-222, 2013.
68. T. D. Gilmore, "Introduction to NF-kappaB: Players, pathways, perspectives," Oncogene, vol. 25, no. 51, pp. 6680-6684, 2006.
69. F. E. Chen and G. Ghosh, "Regulation of DNA binding by Rel/NF-B transcription factors: structural views," Oncogene, vol. 18, no. 49, pp. 6845-6852, 1999.
70. Y. Yamamoto and R. B. Gaynor, "Therapeutic potential of inhibition of the NF-B pathway in the treatment of inflammation and cancer,"The Journal of Clinical Investigation, vol. 107, no. 2, pp. 135-142, 2001.
71. Y. W. Hsum, W. T. Yew, P. L. V. Hong et al. , "Cancer chemopreventive activity of maslinic acid: suppression of COX-2 expression and inhibition of NF-B and AP-1 activation in raji cells," Planta Medica, vol. 77, no. 2, pp. 152-157, 2011.
72. F. J. Reyes-Zurita, G. Pachón-Peña, D. Lizárraga, E. E. Rufino-Palomares,M. Cascante, and J. A. Lupíañez, "The natural triterpene maslinic acid induces apoptosis in HT29 colon cancer cells by a JNK-p53-dependent mechanism," BMC Cancer, vol. 11, article 154, 2011.
73. D.-M. Wu, D. Zhao, D.-Z. Li, D.-Y. Xu, W.-F. Chu, and X.-F. Wang, "Maslinic acid induces apoptosis in salivary gland adenoid cystic carcinoma cells by Ca2+-evoked p38 signaling pathway," Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 383, no. 3, pp. 321-330, 2011.
74. C. Li, Z. Yang, Z. Li et al. , "Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-B and MAPK signaling pathways," Journal of Bone and Mineral Research, vol. 26, no. 3, pp. 644-656, 2011.
75. L. Y. Mooi, W. T. Yew, Y. W. Hsum, K. K. Soo, L. S. Hoon, and Y. C. Chieng, "Suppressive effect of maslinic acid on PMAinduced protein kinase C in human B-lymphoblastoid cells," Asian Pacific Journal of Cancer Prevention, vol. 13, no. 4, pp. 1177-1182, 2012.
76. R. Medeiros, M. F. Otuki, M. C. W. Avellar, and J. B. Calixto, "Mechanisms underlying the inhibitory actions of the pentacyclic triterpene-amyrin in the mouse skin inflammation induced by phorbol ester 12-O-tetradecanoylphorbol-13-acetate," European Journal of Pharmacology, vol. 559, no. 2-3,pp. 227-235, 2007.
77. M. Murakami, Y. Nakatani, G.-I. Atsumi, K. Inoue, and I. Kudo, "Regulatory functions of phospholipase A2," Critical Reviews in Immunology, vol. 17, no. 3-4, pp. 225-283, 1997.
78. J. Xu, Y.-I. Weng, A. Simoni et al. , "Role of PKC and MAPK in cytosolic PLA2 phosphorylation and arachadonic acid release in primary murine astrocytes," Journal of Neurochemistry, vol. 83, no. 2, pp. 259-270, 2002.
79. R. H. Schaloske and E. A. Dennis, "The phospholipase A2 superfamily and its group numbering system," Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1761, no. 11, pp. 1246-1259, 2006.
80. S.-K. Han, E. T. Yoon, and W. Cho, "Bacterial expression and characterization of human secretory class V phospholipase A2," Biochemical Journal, vol. 331, no. 2, pp. 353-357, 1998.
81. S. T. Reddy, M. V. Winstead, J. A. Tischfield, and H. R. Herschman, "Analysis of the secretory phospholipase A2 that mediates prostaglandin production in mast cells," The Journal of Biological Chemistry, vol. 272, no. 21, pp. 13591-13596, 1997.
82. W. H. Yap, B. I. Laweeza Meetoo, and N. Ahemad, "Elucidating themolecular mechanisms of interaction between maslinic acid and human group V-secreted phospholipase A2 (hGV-sPLA2)," in Proceedings of the Joint Malaysia-UK Symposium on Natural Product Chemistry and Drug Discovery, International Medical University, Kuala Lumpur, Malaysia, 2014.